Literature DB >> 26564057

Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user's guide.

Federico Rodriguez-Porcel1,2, Sheheryar Jamali1,2, Andrew P Duker1,2, Alberto J Espay1,2.   

Abstract

Given the wide range of manifestations of parkinsonism and its mimics, the diagnosis may remain elusive or be misattributed in some patients. Dopamine transporter (DAT) single photon emission computed tomography (SPECT) (DaTscan), an imaging technique that probes the integrity of the presynaptic nigrostriatal system, can be useful in the evaluation of clinically complex parkinsonian disorders in the appropriate context and when adequately interpreted. Pearls and pitfalls in the use of DaTscan for the differential diagnosis of parkinsonisms are reviewed using a case-based format. While the DaTscan is no replacement for a careful neurological examination in ascertaining the likelihood of Parkinson disease or other parkinsonisms in most clinical scenarios, it can be useful in the assessment of disorders where an abducting resting tremor, a prominent postural tremor, or incongruent features are not sufficiently clear on exam to distinguish neurodegenerative parkinsonism from dystonia, drug-induced parkinsonism and functional (psychogenic) parkinsonism, respectively.

Entities:  

Keywords:  DaTscan; Parkinson disease; SWEDD; drug-induced parkinsonism; parkinsonism; tremor

Mesh:

Year:  2015        PMID: 26564057     DOI: 10.1586/14737175.2015.1120160

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  2 in total

1.  Drug-induced parkinsonism: A case report.

Authors:  Brianna D Morabito; Barbara Paulison
Journal:  Ment Health Clin       Date:  2018-03-23

Review 2.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.